Cancer - breast news and cancer - breast widget

User AnswersScreen Shot ©Pam StephanI always like hearing from you - you are the experienced survivors, family members, friends, and even health professionals that have some expertise in dealing with...

Whole Grain ProductsPhoto © USDAWe like brown bread at my house. It tastes good and has a texture that will stand up to many different sandwich fillings, or...

Women who took vitamin D and calcium supplements developed breast cancer at the same rate as those who did not take the supplements, according to a study by the Women's health Initiative that is published in the Journal of the National Cancer Institute, the

A small, antibody-like molecule created by researchers at Fox Chase cancer Center can successfully attack two separate molecules on the surface of cancer cells at the same time, halting the growth of breast cancer cells in laboratory tests, the researchers say. The molecule, nickname "ALM," might be a means of slowing cancer spread or, as the researchers believe, a guidance system for delivering more aggressive drugs directly to cancer cells.

About six in 10 breast cancer cases are caused when estrogen triggers cell receptors to promote abnormal cell growth leading to tumors. But if two particular receptors come together in what a University of Wisconsin-Madison researcher calls a "yin yang" relationship, one might knock down the activity of the other and breast cancer growth could be halted.

A new cross-Canada study has found that breast and prostate cancer treatment can foster bone loss. In the online edition of the American Society of Clinical Oncology, the scientists explain how loss of bone mass might affect 46,000 people diagnosed with breast and prostate cancer each year* and place them at increased risk for osteoporosis and fractures. "Our study also looked at possible medications that can reverse or halt bone loss," says Dr.

Title: Booze Taxes Lower Alcohol-Linked DeathsCategory: health newscreated: 11/14/2008 2:00:00 amlast Editorial review: 11/14/2008

Scientists said on Wednesday they found the reason why some women develop resistance to tamoxifen, the key frontline drug against breast cancer. A genetic "switch" prevents tamoxifen from denying cancer cells access to oestrogen, the hormone they need to grow, they said. The study, by a team from Cancer Research UK, is published by the British-based journal Nature. Tamoxifen has played an essential part in slashing the death rate from breast cancer in advanced economies. It is used in cases of so-called hormone-sensitive, or hormone-receptor-positive, cancer. These are tumours that are stimulated by exposure to the female hormone, oestrogen. Tamoxifen is given to most women for five years after they have been diagnosed with c...

TORONTO -- Vitamin D may not have the cancer preventive powers proponents ascribe to it, at least in so far as breast cancer is concerned, a new study suggests. The work, published Tuesday in the Journal of the National Cancer Institute, showed women who took 400 international units of vitamin D along with 1,000 milligrams of calcium for seven years were no less likely than women who took placebo pills to develop breast cancer. The lead author, medical oncologist Dr. Rowan Chlebowski, said the results of the study may put "a little bit of the brakes on the bandwagon" promoting vitamin D as a cancer prevention tool. "What this does, it says you've got to step back and look at it in a different light," Chlebowski, who is with the Los...

IntroductionInterleukin (IL)-17 plays an important role in autoimmunity, promoting auto-immunity, inflammation and invasion in multiple sclerosis, rheumatoid arthritis and type-I diabetes. However, its role in cancer is unclear as there are few studies examining IL-17 protein expression in cancer. Therefore, we examined IL-17 protein expression in human breast cancer and modelled its potential biological significance in vitro. Methods: Immunohistochemistry was used to determine IL-17 expression in breast cancers. Matrigel invasion assays were employed to examine the effect of IL-17 on cancer cell invasion by a panel of breast cancer cell lines. The role of matrix metalloproteinases (MMPs) was investigated with selective antagonists and immunoassays for MMPs-2, 3, 9 and tissue inhibitor of MMP (TIMP1). Results: IL-17 expressing cells with macrophage morphology were identified in the peri-tumoural area of a proportion of patients (8/19). Macrophages were confirmed by CD68 staining